Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Research And Development Expense of $1.90 million for the year ending 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -7.5% in Research And Development Expense from 2024 to 2025.
- This data is from PROVECTUS BIOPHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $2.13 million | Q3 2010: $3.62 million | Q1 2011: $1.52 million | Q2 2011: $2.01 million | Q3 2011: $3.44 million | Q1 2012: $1.57 million | Q2 2012: $1.66 million | Q3 2012: $1.13 million | Q1 2013: $740.5 thousand | Q2 2013: $778.3 thousand | Q3 2013: $1.30 million | Q1 2014: $1.16 million | Q2 2014: $1.03 million | Q3 2014: $1.36 million | Q1 2015: $2.45 million | Q2 2015: $2.22 million | Q3 2015: $2.86 million | Q1 2016: $2.41 million | Q2 2016: $2.00 million | Q3 2016: $2.46 million | Q1 2017: $1.75 million | Q2 2017: $2.25 million | Q3 2017: $2.26 million | Q1 2018: $1.94 million | Q2 2018: $987.2 thousand | Q3 2018: $528.4 thousand | Q1 2019: $1.04 million | Q2 2019: $1.21 million | Q3 2019: $1.00 million | Q1 2020: $909.4 thousand | Q2 2020: $696.5 thousand | Q3 2020: $667.5 thousand | Q1 2021: $655.1 thousand | Q2 2021: $603.0 thousand | Q3 2021: $608.7 thousand | Q1 2022: $671.1 thousand | Q2 2022: $816.6 thousand | Q3 2022: $580.4 thousand | Q1 2023: $548.4 thousand | Q2 2023: $434.2 thousand | Q3 2023: $350.8 thousand | Q1 2024: $555.5 thousand | Q2 2024: $472.9 thousand | Q3 2024: $414.0 thousand | Q1 2025: $388.8 thousand | Q2 2025: $867.3 thousand | Q3 2025: $345.9 thousand.
- Over the full 17 years of available data (2009 to 2025), PROVECTUS BIOPHARMACEUTICALS, INC.'s Research And Development Expense has declined by 61.4%.
- Historical annual values: Fiscal year 2025: $1.90 million | Fiscal year 2024: $2.05 million | Fiscal year 2023: $1.75 million | Fiscal year 2022: $2.39 million | Fiscal year 2021: $2.61 million | Fiscal year 2020: $2.81 million | Fiscal year 2019: $4.00 million | Fiscal year 2018: $4.75 million | Fiscal year 2017: $8.20 million | Fiscal year 2016: $8.21 million | Fiscal year 2015: $11.38 million | Fiscal year 2014: $5.81 million | Fiscal year 2013: $3.60 million | Fiscal year 2012: $5.01 million | Fiscal year 2011: $8.81 million | Fiscal year 2010: $8.42 million | Fiscal year 2009: $4.91 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: